首页 > 最新文献

Leukemia research最新文献

英文 中文
Adipose tissue indices predict prognosis in hodgkin lymphoma 预测霍奇金淋巴瘤预后的脂肪组织指数
IF 2.7 4区 医学 Q2 Medicine Pub Date : 2024-02-15 DOI: 10.1016/j.leukres.2024.107457
Demircan Özbalcı , Mehmet Erdoğan , Emine Güçhan Alanoğlu , Sevim Süreyya Şengül , Kamuran Yüceer , Hande Nur Eroğlu , Samet Yağcı

Introduction background

This study evaluated the impact of adipose tissue indices on prognosis of HL.

Methods

Fifty-five patients with newly diagnosed Hodgkin Lymphoma were evaluated retrospectively for association with adipose tissue indices (total abdominal tissue volume, radiodensity, subcutaneous and visceral adipose tissue SUVmax value and prognostic factors for Hodgkin Lymphoma such as IPS-3, IPS-7, stage, sedimentation, progression free and overall survival.

Results

For IPS-3, SAT SUVmax and TAAT radiodensity were significantly increased in high-risk patients (2and 3) compared to group 0 and 1. For IPS-7, total abdominal adipose volume was significantly decreased in high-risk patients, SAT SUVmax significantly increased in high-risk patients and decreased in low-risk patients. In addition, SAT SUVmax was significantly increased in patients with high sedimentation rate, with B symptoms and who passed away during follow-up. SAT SUVmax showed moderate positive correlation with sedimentation, IPS-3, IPS-7, and stage. In addition, it was observed that TAAT radiodensity and SAT SUVmax were significantly better for determining prognosis than other adipose tissue indices. Roc analysis showed that the diagnostic value of all adipose tissue indices in predicting IPS-3 and IPS-7 prognoses were statistically significant.

Conclusion

SAT SUVmax and TAAT radiodensity were two new and independent markers with diagnostic value in predicting prognosis.

方法回顾性评估55例新诊断的霍奇金淋巴瘤患者的脂肪组织指数(腹部组织总体积、放射性密度、皮下和内脏脂肪组织SUVmax值)与霍奇金淋巴瘤预后因素(如IPS-3、IPS-7、分期、血沉、无进展生存期和总生存期)的相关性。结果 在IPS-3中,与0组和1组相比,高危患者(2组和3组)的SAT SUVmax和TAAT放射密度明显增加。 在IPS-7中,高危患者的腹部脂肪总量明显减少,SAT SUVmax在高危患者中明显增加,在低危患者中减少。此外,血沉高、有 B 型症状和在随访期间去世的患者的 SAT SUVmax 明显增高。SAT SUVmax 与血沉、IPS-3、IPS-7 和分期呈中度正相关。此外,还观察到 TAAT 放射性密度和 SAT SUVmax 在判断预后方面明显优于其他脂肪组织指数。Roc分析表明,所有脂肪组织指数在预测IPS-3和IPS-7预后方面的诊断价值均具有统计学意义。
{"title":"Adipose tissue indices predict prognosis in hodgkin lymphoma","authors":"Demircan Özbalcı ,&nbsp;Mehmet Erdoğan ,&nbsp;Emine Güçhan Alanoğlu ,&nbsp;Sevim Süreyya Şengül ,&nbsp;Kamuran Yüceer ,&nbsp;Hande Nur Eroğlu ,&nbsp;Samet Yağcı","doi":"10.1016/j.leukres.2024.107457","DOIUrl":"10.1016/j.leukres.2024.107457","url":null,"abstract":"<div><h3>Introduction background</h3><p>This study evaluated the impact of adipose tissue indices on prognosis of HL.</p></div><div><h3>Methods</h3><p>Fifty-five patients with newly diagnosed Hodgkin Lymphoma were evaluated retrospectively for association with adipose tissue indices (total abdominal tissue volume, radiodensity, subcutaneous and visceral adipose tissue SUVmax value and prognostic factors for Hodgkin Lymphoma such as IPS-3, IPS-7, stage, sedimentation, progression free and overall survival.</p></div><div><h3>Results</h3><p>For IPS-3, SAT SUVmax and TAAT radiodensity were significantly increased in high-risk patients (2and 3) compared to group 0 and 1. For IPS-7, total abdominal adipose volume was significantly decreased in high-risk patients, SAT SUVmax significantly increased in high-risk patients and decreased in low-risk patients. In addition, SAT SUVmax was significantly increased in patients with high sedimentation rate, with B symptoms and who passed away during follow-up. SAT SUVmax showed moderate positive correlation with sedimentation, IPS-3, IPS-7, and stage. In addition, it was observed that TAAT radiodensity and SAT SUVmax were significantly better for determining prognosis than other adipose tissue indices. Roc analysis showed that the diagnostic value of all adipose tissue indices in predicting IPS-3 and IPS-7 prognoses were statistically significant.</p></div><div><h3>Conclusion</h3><p>SAT SUVmax and TAAT radiodensity were two new and independent markers with diagnostic value in predicting prognosis.</p></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139889352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bortezomib modulated the autophagy-lysosomal pathway in a TFEB-dependent manner in multiple myeloma 硼替佐米以 TFEB 依赖性方式调节多发性骨髓瘤的自噬-溶酶体通路
IF 2.7 4区 医学 Q2 Medicine Pub Date : 2024-02-12 DOI: 10.1016/j.leukres.2024.107455
Rongjuan Zhang , Xinhong Yang , Xiaomin Shi , Enhong Xing , Lihong Wang , Changlai Hao , Zhihua Zhang

Objective

To explore the involvement of TFEB-mediated autophagy-lysosomal mechanisms in multiple myeloma (MM) during bortezomib treatment.

Methods

MM cells were exposed to bortezomib or subjected to TFEB knockdown. CCK assay was used to assess the cell proliferation. Western blotting and fluorescent staining were conducted to examine autophagy and lysosomes. The TFEB expression pattern was analyzed, and whole transcriptome sequencing was carried out. Additionally, TFEB target genes were predicted using the GTRD(http://gtrd.biouml.org/) website, and pathway analysis was performed.

Results

Bortezomib demonstrated a dose-dependent and time dependent inhibition of cell proliferation. In MM cells treated with bortezomib, LC3B, Beclin-1, TFEB, and Lamp1 exhibited upregulation in a time- and concentration-dependent manner. LysoTracker dye labeling showed an increase in lysosomes in the bortezomib-treated group. Moreover, bortezomib elevated the expression of lysosome-associated factor Lamp1. Bortezomib promoted the nuclear translocation of TFEB, leading to decreased cytoplasmic TFEB and increased nuclear TFEB. TFEB gene silencing reversed bortezomib's inhibitory effect on MM cell lines, significantly reducing autophagosome expression and lysosome numbers. Furthermore, bioinformatic analysis identified the MAPK pathway as a potential downstream target of TFEB.

Conclusion

Bortezomib effectively inhibits MM cell proliferation and induces autophagy, partly through TFEB-mediated mechanisms, with potential involvement of the MAPK pathway.

方法 将多发性骨髓瘤(MM)细胞暴露于硼替佐米或敲除 TFEB。采用 CCK 检测法评估细胞增殖情况。用 Western 印迹法和荧光染色法检测自噬和溶酶体。分析了 TFEB 的表达模式,并进行了全转录组测序。此外,还利用 GTRD(http://gtrd.biouml.org/) 网站预测了 TFEB 的靶基因,并进行了通路分析。结果硼替佐米对细胞增殖的抑制具有剂量依赖性和时间依赖性。在用硼替佐米处理的 MM 细胞中,LC3B、Beclin-1、TFEB 和 Lamp1 呈时间和浓度依赖性上调。溶酶体追踪染料标记显示,硼替佐米处理组的溶酶体有所增加。此外,硼替佐米还能提高溶酶体相关因子Lamp1的表达。硼替佐米促进了TFEB的核转位,导致细胞质中的TFEB减少,而细胞核中的TFEB增加。TFEB基因沉默可逆转硼替佐米对MM细胞株的抑制作用,显著减少自噬体的表达和溶酶体的数量。结论硼替佐米能有效抑制 MM 细胞增殖并诱导自噬,部分是通过 TFEB 介导的机制,MAPK 途径也可能参与其中。
{"title":"Bortezomib modulated the autophagy-lysosomal pathway in a TFEB-dependent manner in multiple myeloma","authors":"Rongjuan Zhang ,&nbsp;Xinhong Yang ,&nbsp;Xiaomin Shi ,&nbsp;Enhong Xing ,&nbsp;Lihong Wang ,&nbsp;Changlai Hao ,&nbsp;Zhihua Zhang","doi":"10.1016/j.leukres.2024.107455","DOIUrl":"10.1016/j.leukres.2024.107455","url":null,"abstract":"<div><h3>Objective</h3><p>To explore the involvement of TFEB-mediated autophagy-lysosomal mechanisms in multiple myeloma (MM) during bortezomib treatment.</p></div><div><h3>Methods</h3><p>MM cells were exposed to bortezomib or subjected to TFEB knockdown. CCK assay was used to assess the cell proliferation. Western blotting and fluorescent staining were conducted to examine autophagy and lysosomes. The TFEB expression pattern was analyzed, and whole transcriptome sequencing was carried out. Additionally, TFEB target genes were predicted using the GTRD(http://gtrd.biouml.org/) website, and pathway analysis was performed.</p></div><div><h3>Results</h3><p>Bortezomib demonstrated a dose-dependent and time dependent inhibition of cell proliferation. In MM cells treated with bortezomib, LC3B, Beclin-1, TFEB, and Lamp1 exhibited upregulation in a time- and concentration-dependent manner. LysoTracker dye labeling showed an increase in lysosomes in the bortezomib-treated group. Moreover, bortezomib elevated the expression of lysosome-associated factor Lamp1. Bortezomib promoted the nuclear translocation of TFEB, leading to decreased cytoplasmic TFEB and increased nuclear TFEB. TFEB gene silencing reversed bortezomib's inhibitory effect on MM cell lines, significantly reducing autophagosome expression and lysosome numbers. Furthermore, bioinformatic analysis identified the MAPK pathway as a potential downstream target of TFEB.</p></div><div><h3>Conclusion</h3><p>Bortezomib effectively inhibits MM cell proliferation and induces autophagy, partly through TFEB-mediated mechanisms, with potential involvement of the MAPK pathway.</p></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139829517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emergence of secondary fusions in chronic myeloid leukemia as a driver of tyrosine kinase inhibitor resistance and blast crisis transformation 慢性髓性白血病继发性融合的出现是酪氨酸激酶抑制剂耐药性和暴发性危机转化的驱动因素
IF 2.7 4区 医学 Q2 Medicine Pub Date : 2024-02-01 DOI: 10.1016/j.leukres.2024.107439
Lara Boucher, Laura Rozalska, Nathalie Sorel, Gaëlle Olivier, Maria Pilar Gallego Hernanz, Emilie Cayssials, Anna Raimbault, Jean-Claude Chomel
{"title":"Emergence of secondary fusions in chronic myeloid leukemia as a driver of tyrosine kinase inhibitor resistance and blast crisis transformation","authors":"Lara Boucher,&nbsp;Laura Rozalska,&nbsp;Nathalie Sorel,&nbsp;Gaëlle Olivier,&nbsp;Maria Pilar Gallego Hernanz,&nbsp;Emilie Cayssials,&nbsp;Anna Raimbault,&nbsp;Jean-Claude Chomel","doi":"10.1016/j.leukres.2024.107439","DOIUrl":"10.1016/j.leukres.2024.107439","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139554363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Myelodysplastic neoplasms evolving from inherited bone marrow failure syndromes / germline predisposition syndromes: Back under the microscope 骨髓增生异常肿瘤从遗传性骨髓衰竭综合征/基因易感性综合征演变而来:回到显微镜下
IF 2.7 4区 医学 Q2 Medicine Pub Date : 2024-02-01 DOI: 10.1016/j.leukres.2024.107441
M. Tarek Elghetany , Mrinal M. Patnaik , Joseph D. Khoury

Inherited bone marrow failure syndromes and germline predisposition syndromes (IBMFS/GPS) are associated with increased risk for hematologic malignancies, particularly myeloid neoplasms, such as myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML). The diagnosis of MDS in these syndromes poses difficulty due to frequent bone marrow hypocellularity and the presence of some degree of dysplastic features related to the underlying germline defect causing abnormal maturation of one or more cell lines. Yet, the diagnosis of MDS is usually associated with a worse outcome in several IBMFS/GPS. Criteria for the diagnosis of MDS in IBMFS/GPS have not been standardized with some authors suggesting a mixture of morphologic, cytogenetic, and genetic criteria. This review highlights these challenges and suggests a more standardized approach to nomenclature and diagnostic criteria.

遗传性骨髓衰竭综合征和种系易感综合征(IBMFS/GPS)与罹患血液系统恶性肿瘤的风险增加有关,尤其是骨髓性肿瘤,如骨髓增生异常性肿瘤(MDS)和急性髓系白血病(AML)。在这些综合征中,骨髓增生异常性肿瘤(MDS)的诊断非常困难,因为骨髓细胞功能经常低下,而且存在一定程度的发育不良特征,这与导致一个或多个细胞系异常成熟的潜在种系缺陷有关。然而,在一些 IBMFS/GPS 中,MDS 的诊断通常与较差的预后相关。IBMFS/GPS 中 MDS 的诊断标准尚未标准化,一些学者建议混合使用形态学、细胞遗传学和遗传学标准。本综述强调了这些挑战,并建议对术语和诊断标准采用更标准化的方法。
{"title":"Myelodysplastic neoplasms evolving from inherited bone marrow failure syndromes / germline predisposition syndromes: Back under the microscope","authors":"M. Tarek Elghetany ,&nbsp;Mrinal M. Patnaik ,&nbsp;Joseph D. Khoury","doi":"10.1016/j.leukres.2024.107441","DOIUrl":"10.1016/j.leukres.2024.107441","url":null,"abstract":"<div><p><span><span><span>Inherited bone marrow failure syndromes and </span>germline predisposition syndromes (IBMFS/GPS) are associated with increased risk for </span>hematologic malignancies, particularly myeloid neoplasms, such as myelodysplastic neoplasms (MDS) and </span>acute myeloid leukemia<span> (AML). The diagnosis of MDS in these syndromes poses difficulty due to frequent bone marrow hypocellularity and the presence of some degree of dysplastic features related to the underlying germline defect causing abnormal maturation of one or more cell lines. Yet, the diagnosis of MDS is usually associated with a worse outcome in several IBMFS/GPS. Criteria for the diagnosis of MDS in IBMFS/GPS have not been standardized with some authors suggesting a mixture of morphologic, cytogenetic, and genetic criteria. This review highlights these challenges and suggests a more standardized approach to nomenclature and diagnostic criteria.</span></p></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139554438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase 2 trial of induction with dasatinib and consolidation with hyper-CVAD plus dasatinib followed by allografting for Ph-positive acute lymphoblastic leukemia in adults 用达沙替尼诱导和超CVAD加达沙替尼巩固治疗成人Ph阳性急性淋巴细胞白血病并进行异体移植的2期试验
IF 2.7 4区 医学 Q2 Medicine Pub Date : 2024-02-01 DOI: 10.1016/j.leukres.2024.107438
Iekuni Oh, Kaoru Hatano, Takashi Ikeda, Yumiko Toda, Daisuke Minakata, Shinichiro Kawaguchi, Kaoru Morita, Chihiro Yamamoto, Masahiro Ashizawa, Kazuya Sato, Kazuaki Kameda, Ayumi Gomyo, Yukiko Misaki, Shunto Kawamura, Shunichi Kimura, Hiroyuki Kobayashi, Hiroyuki Sato, Hideki Nakasone, Ken Ohmine, Shinichiro Fujiwara, Yoshinobu Kanda
{"title":"Phase 2 trial of induction with dasatinib and consolidation with hyper-CVAD plus dasatinib followed by allografting for Ph-positive acute lymphoblastic leukemia in adults","authors":"Iekuni Oh,&nbsp;Kaoru Hatano,&nbsp;Takashi Ikeda,&nbsp;Yumiko Toda,&nbsp;Daisuke Minakata,&nbsp;Shinichiro Kawaguchi,&nbsp;Kaoru Morita,&nbsp;Chihiro Yamamoto,&nbsp;Masahiro Ashizawa,&nbsp;Kazuya Sato,&nbsp;Kazuaki Kameda,&nbsp;Ayumi Gomyo,&nbsp;Yukiko Misaki,&nbsp;Shunto Kawamura,&nbsp;Shunichi Kimura,&nbsp;Hiroyuki Kobayashi,&nbsp;Hiroyuki Sato,&nbsp;Hideki Nakasone,&nbsp;Ken Ohmine,&nbsp;Shinichiro Fujiwara,&nbsp;Yoshinobu Kanda","doi":"10.1016/j.leukres.2024.107438","DOIUrl":"10.1016/j.leukres.2024.107438","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139507948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Systematic review and meta-analysis evaluating clinical outcomes in adult acute myeloid leukemia patients with central nervous system involvement 评估中枢神经系统受累的成人急性髓性白血病患者临床疗效的系统综述和荟萃分析
IF 2.7 4区 医学 Q2 Medicine Pub Date : 2024-02-01 DOI: 10.1016/j.leukres.2024.107452
Hannah Goulart , Dahniel Sastow , Erin Moshier , Lily Martin , John Mascarenhas , Douglas Tremblay

Patients with acute myeloid leukemia (AML) may experience extramedullary involvement when disease is present outside of the blood and bone marrow. In particular, the presence of central nervous system (CNS) involvement has traditionally been thought of as a poor prognostic factor. In the presently available literature, there is a paucity of conclusive data surrounding CNS AML given its rarity and lack of unified screening practices. Thus, we performed a systematic review and meta-analysis in order to more definitively characterize survival outcomes in this patient population. In this meta-analysis, we evaluated survival outcomes and response rates from clinical studies on patients with AML stratified by the presence of CNS involvement. Twelve studies were included in the meta-analysis with a resulting hazard ratio (HR) for overall survival (OS) of 1.34 with a 95 % CI of 1.14 to 1.58. These findings suggest that CNS involvement in adult patients with AML is associated with an increased hazard of mortality compared to those patients without CNS involvement. As such, CNS involvement should be viewed as negative prognostic marker, and attention should be made to ensure prompt identification and treatment of patients who experience this complication.

急性髓性白血病(AML)患者可能会出现髓外受累,即疾病出现在血液和骨髓之外。尤其是中枢神经系统(CNS)受累,历来被认为是预后不良的因素。在现有的文献中,由于中枢神经系统急性髓细胞白血病罕见且缺乏统一的筛查方法,因此有关中枢神经系统急性髓细胞白血病的确凿数据很少。因此,我们进行了一项系统回顾和荟萃分析,以更明确地描述这一患者群体的生存结果。在这项荟萃分析中,我们评估了按中枢神经系统受累情况分层的急性髓细胞性白血病患者临床研究的生存结果和反应率。荟萃分析共纳入了 12 项研究,结果显示总生存率 (OS) 的危险比 (HR) 为 1.34,95 % CI 为 1.14 至 1.58。这些研究结果表明,与无中枢神经系统受累的患者相比,成年急性髓细胞性白血病患者的中枢神经系统受累与死亡率增加有关。因此,中枢神经系统受累应被视为预后的负面指标,应注意确保及时发现和治疗出现这种并发症的患者。
{"title":"Systematic review and meta-analysis evaluating clinical outcomes in adult acute myeloid leukemia patients with central nervous system involvement","authors":"Hannah Goulart ,&nbsp;Dahniel Sastow ,&nbsp;Erin Moshier ,&nbsp;Lily Martin ,&nbsp;John Mascarenhas ,&nbsp;Douglas Tremblay","doi":"10.1016/j.leukres.2024.107452","DOIUrl":"https://doi.org/10.1016/j.leukres.2024.107452","url":null,"abstract":"<div><p>Patients with acute myeloid leukemia (AML) may experience extramedullary involvement when disease is present outside of the blood and bone marrow. In particular, the presence of central nervous system (CNS) involvement has traditionally been thought of as a poor prognostic factor. In the presently available literature, there is a paucity of conclusive data surrounding CNS AML given its rarity and lack of unified screening practices. Thus, we performed a systematic review and meta-analysis in order to more definitively characterize survival outcomes in this patient population. In this meta-analysis, we evaluated survival outcomes and response rates from clinical studies on patients with AML stratified by the presence of CNS involvement. Twelve studies were included in the meta-analysis with a resulting hazard ratio (HR) for overall survival (OS) of 1.34 with a 95 % CI of 1.14 to 1.58. These findings suggest that CNS involvement in adult patients with AML is associated with an increased hazard of mortality compared to those patients without CNS involvement. As such, CNS involvement should be viewed as negative prognostic marker, and attention should be made to ensure prompt identification and treatment of patients who experience this complication.</p></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139709733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Circ_0005615 enhances multiple myeloma progression through interaction with EIF4A3 to regulate MAP3K4 m6A modification mediated by ALKBH5 Circ_0005615 通过与 EIF4A3 相互作用来调控 ALKBH5 介导的 MAP3K4 m6A 修饰,从而促进多发性骨髓瘤的进展
IF 2.7 4区 医学 Q2 Medicine Pub Date : 2024-02-01 DOI: 10.1016/j.leukres.2024.107451
Kai Zhu , Fengquan Gou , Ziwen Zhao , Ke Xu , Jian Song , Hongyi Jiang , Feng Zhang , Yanli Yang , Jiajia Li

Background

Circular RNAs (circRNAs) are associated with development and progression of multiple myeloma (MM). However, the role and mechanism of circ_0005615 in MM have not been elucidated.

Methods

Circ_0005615 was determined by GEO database. quantitative RT-PCR was performed to confirm the expression of circ_0005615 in peripheral blood of MM patients and MM cells. The roles of circ_0005615 in MM were analyzed using CCK8, transwell invasion, cell apoptosis and tumor xenograft experiments. Bioinformatics tools, RIP and RNA pull down assays were conducted to explore the downstream of circ_0005615. Furthermore, the mechanism was investigated by quantitative RT-PCR, western blot, dot blot and meRIP-PCR assays.

Results

Circ_0005615 was upregulated in MM. Overexpression of circ_0005615 promoted cell viability and invasion, and suppressed apoptosis in vitro, which were opposite when circ_0005615 was knockdowned. Mechanistically, EIF4A3, a RNA-binding protein (RBP), could directly bind to circ_0005615 and ALKBH5, where ALKBH5 could directly combine with MAP3K4, forming a circ_0005615- EIF4A3-ALKBH5-MAP3K4 module. Furthermore, circ_0005615 overexpression increased m6A methylation of MAP3K4 by inhibiting ALKBH5, leading to decreased MAP3K4. Further functional experiments indicated that ALKBH5 overexpression weakened the promoting roles of circ_0005615 overexpression in MAP3K4 m6A methylation and tumor progression in MM. The above functions and mechanism were also verified in vivo.

Conclusions

Elevated circ_0005615 decreased MAP3K4 mediated by ALKBH5 through interacting with EIF4A3, thereby accelerating MM progression. Circ_0005615 might be a promising biomarker and target of MM.

背景环状核糖核酸(circRNA)与多发性骨髓瘤(MM)的发生和发展有关。方法通过 GEO 数据库确定了 circ_0005615 的表达量。利用CCK8、Transwell侵袭、细胞凋亡和肿瘤异种移植实验分析了circ_0005615在MM中的作用。通过生物信息学工具、RIP 和 RNA pull down 试验来探索 circ_0005615 的下游作用。结果circ_0005615在MM中上调。结果circ_0005615在MM中上调,过表达circ_0005615可促进细胞活力和侵袭,抑制体外细胞凋亡,而敲除circ_0005615则相反。从机制上看,RNA结合蛋白(RBP)EIF4A3可直接与circ_0005615和ALKBH5结合,ALKBH5可直接与MAP3K4结合,形成circ_0005615- EIF4A3-ALKBH5-MAP3K4 模块。此外,circ_0005615 的过表达通过抑制 ALKBH5 增加了 MAP3K4 的 m6A 甲基化,从而导致 MAP3K4 的减少。进一步的功能实验表明,ALKBH5的过表达削弱了circ_0005615过表达对MM中MAP3K4 m6A甲基化和肿瘤进展的促进作用。结论高表达的circ_0005615通过与EIF4A3相互作用,降低了ALKBH5介导的MAP3K4,从而加速了MM的进展。Circ_0005615可能是一种有前景的MM生物标记物和靶标。
{"title":"Circ_0005615 enhances multiple myeloma progression through interaction with EIF4A3 to regulate MAP3K4 m6A modification mediated by ALKBH5","authors":"Kai Zhu ,&nbsp;Fengquan Gou ,&nbsp;Ziwen Zhao ,&nbsp;Ke Xu ,&nbsp;Jian Song ,&nbsp;Hongyi Jiang ,&nbsp;Feng Zhang ,&nbsp;Yanli Yang ,&nbsp;Jiajia Li","doi":"10.1016/j.leukres.2024.107451","DOIUrl":"10.1016/j.leukres.2024.107451","url":null,"abstract":"<div><h3>Background</h3><p>Circular RNAs (circRNAs) are associated with development and progression of multiple myeloma (MM). However, the role and mechanism of circ_0005615 in MM have not been elucidated.</p></div><div><h3>Methods</h3><p>Circ_0005615 was determined by GEO database. quantitative RT-PCR was performed to confirm the expression of circ_0005615 in peripheral blood of MM patients and MM cells. The roles of circ_0005615 in MM were analyzed using CCK8, transwell invasion, cell apoptosis and tumor xenograft experiments. Bioinformatics tools, RIP and RNA pull down assays were conducted to explore the downstream of circ_0005615. Furthermore, the mechanism was investigated by quantitative RT-PCR, western blot, dot blot and meRIP-PCR assays.</p></div><div><h3>Results</h3><p>Circ_0005615 was upregulated in MM. Overexpression of circ_0005615 promoted cell viability and invasion, and suppressed apoptosis <em>in vitro</em>, which were opposite when circ_0005615 was knockdowned. Mechanistically, EIF4A3, a RNA-binding protein (RBP), could directly bind to circ_0005615 and ALKBH5, where ALKBH5 could directly combine with MAP3K4, forming a circ_0005615- EIF4A3-ALKBH5-MAP3K4 module. Furthermore, circ_0005615 overexpression increased m6A methylation of MAP3K4 by inhibiting ALKBH5, leading to decreased MAP3K4. Further functional experiments indicated that ALKBH5 overexpression weakened the promoting roles of circ_0005615 overexpression in MAP3K4 m6A methylation and tumor progression in MM. The above functions and mechanism were also verified <em>in vivo</em>.</p></div><div><h3>Conclusions</h3><p>Elevated circ_0005615 decreased MAP3K4 mediated by ALKBH5 through interacting with EIF4A3, thereby accelerating MM progression. Circ_0005615 might be a promising biomarker and target of MM.</p></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139663308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
When the devil is in the details: Similarities and differences between WHO and ICC classifications of AML 细节决定成败:世界卫生组织和国际协调委员会对急性髓细胞白血病分类的异同
IF 2.7 4区 医学 Q2 Medicine Pub Date : 2024-01-17 DOI: 10.1016/j.leukres.2024.107440
Sergio Ramos-Cillan, Daniel Láinez-González, Laura Solan, Carlos Blas, Rocío Salgado, Tamara Castaño, Javier Cornago, Pilar Llamas, Juan Manuel Alonso-Dominguez
{"title":"When the devil is in the details: Similarities and differences between WHO and ICC classifications of AML","authors":"Sergio Ramos-Cillan,&nbsp;Daniel Láinez-González,&nbsp;Laura Solan,&nbsp;Carlos Blas,&nbsp;Rocío Salgado,&nbsp;Tamara Castaño,&nbsp;Javier Cornago,&nbsp;Pilar Llamas,&nbsp;Juan Manuel Alonso-Dominguez","doi":"10.1016/j.leukres.2024.107440","DOIUrl":"https://doi.org/10.1016/j.leukres.2024.107440","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139503536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Altered lipid metabolism in patients with acute graft-versus-host disease after allogeneic hematopoietic cell transplantation 异基因造血细胞移植后急性移植物抗宿主疾病患者的脂质代谢改变。
IF 2.7 4区 医学 Q2 Medicine Pub Date : 2024-01-05 DOI: 10.1016/j.leukres.2024.107435
Martyna Tyszka , Dominika Maciejewska-Markiewicz , Daniel Styburski , Jarosław Biliński , Agnieszka Tomaszewska , Ewa Stachowska , Grzegorz W. Basak

Allogeneic hematopoietic cell transplantation (allo-HCT) remains the sole curative option for many hematological malignancies and other diseases. Nevertheless, its application is limited due to the risk of life-threatening complications, mainly graft-versus-host disease (GVHD). Currently, in clinical practice, the risk of developing GVHD is estimated for every patient based on factors related to the donor and the host. In our prospective, observational study, we analyzed serum from 38 patients undergoing allo-HCT at our institution. We compared the metabolic profiles of patients who developed acute GVHD (aGVHD) with those without such complication by identification and comparison of metabolites masses on the XCMS platform. We observed that patients diagnosed with aGVHD had different metabolic profiles compared to the remaining patients and this alteration was noticeable already 7 days before the procedure. We identified dysregulated metabolites involved in bile acid transformation and cholesterol synthesis. Our study of the untargeted metabolome in allo-HCT recipients has revealed a potential link between lipid metabolism, specifically involving bile acid transformation and cholesterol synthesis, and the development of aGVHD. This finding might be an important indication for future research focused on understanding GVHD development, discovering prediction models, and investigating possible prophylactic interventions.

异基因造血细胞移植(allo-HCT)仍然是治疗许多血液恶性肿瘤和其他疾病的唯一方法。然而,由于存在危及生命的并发症风险,主要是移植物抗宿主疾病(GVHD),其应用受到了限制。目前,在临床实践中,我们根据供体和宿主的相关因素来估计每位患者发生移植物抗宿主疾病的风险。通过在 XCMS 平台上识别和比较代谢产物的质量,我们比较了发生急性 GVHD 的患者和未发生这种并发症的患者的代谢概况。我们观察到,确诊为急性 GVHD 的患者与其他患者的代谢概况不同,而且这种变化在手术前 7 天就已经很明显了。我们对allo-HCT受者非靶向代谢组的研究揭示了脂质代谢(特别是胆汁酸转化和胆固醇合成)与发生 aGVHD 之间的潜在联系。这一发现可能是未来研究的一个重要指标,研究的重点是了解GVHD的发展、发现预测模型以及调查可能的预防性干预措施。
{"title":"Altered lipid metabolism in patients with acute graft-versus-host disease after allogeneic hematopoietic cell transplantation","authors":"Martyna Tyszka ,&nbsp;Dominika Maciejewska-Markiewicz ,&nbsp;Daniel Styburski ,&nbsp;Jarosław Biliński ,&nbsp;Agnieszka Tomaszewska ,&nbsp;Ewa Stachowska ,&nbsp;Grzegorz W. Basak","doi":"10.1016/j.leukres.2024.107435","DOIUrl":"10.1016/j.leukres.2024.107435","url":null,"abstract":"<div><p>Allogeneic hematopoietic cell transplantation<span> (allo-HCT) remains the sole curative option for many hematological malignancies<span><span> and other diseases. Nevertheless, its application is limited due to the risk of life-threatening complications, mainly graft-versus-host disease (GVHD). Currently, in clinical practice, the risk of developing GVHD is estimated for every patient based on factors related to the donor and the host. In our prospective, observational study, we analyzed serum from 38 patients undergoing allo-HCT at our institution. We compared the metabolic profiles of patients who developed acute GVHD (aGVHD) with those without such complication by identification and comparison of metabolites masses on the XCMS platform. We observed that patients diagnosed with aGVHD had different metabolic profiles compared to the remaining patients and this alteration was noticeable already 7 days before the procedure. We identified dysregulated metabolites involved in </span>bile acid<span><span> transformation and cholesterol synthesis. Our study of the untargeted </span>metabolome<span> in allo-HCT recipients has revealed a potential link between lipid metabolism, specifically involving bile acid transformation and cholesterol synthesis, and the development of aGVHD. This finding might be an important indication for future research focused on understanding GVHD development, discovering prediction models, and investigating possible prophylactic interventions.</span></span></span></span></p></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139373663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Spectrum of therapy-related clonal cytopenias and neoplasms after exposure to Lutetium-177-Dotatate 暴露于镥-177-点位酸盐后与治疗相关的克隆性细胞减少症和肿瘤的范围
IF 2.7 4区 医学 Q2 Medicine Pub Date : 2024-01-01 DOI: 10.1016/j.leukres.2023.107434
Stephanie L. Pritzl, Yael Kusne, Thorvardur R. Halfdanarson, Timothy Hobday, Mohamad Bassam Sonbol, Ayse Tuba Kendi, Abhishek A. Mangaonkar, Naseema Gangat, Mithun Shah, Mrinal M. Patnaik
{"title":"Spectrum of therapy-related clonal cytopenias and neoplasms after exposure to Lutetium-177-Dotatate","authors":"Stephanie L. Pritzl,&nbsp;Yael Kusne,&nbsp;Thorvardur R. Halfdanarson,&nbsp;Timothy Hobday,&nbsp;Mohamad Bassam Sonbol,&nbsp;Ayse Tuba Kendi,&nbsp;Abhishek A. Mangaonkar,&nbsp;Naseema Gangat,&nbsp;Mithun Shah,&nbsp;Mrinal M. Patnaik","doi":"10.1016/j.leukres.2023.107434","DOIUrl":"10.1016/j.leukres.2023.107434","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139051442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Leukemia research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1